Over the next year, it’s estimated the U.S. could see up to 20,240 cases on acute myeloid leukemia, with a five-year survival rate of 29.5%, according to the National Cancer Institute. It’s also been estimated the U.S. could see up to 11,400 deaths associated with the cancer, as well.
As you may know, acute myeloid leukemia (AML) is a type of cancer of the bone marrow and blood. With it, “blood stem cells begin to function abnormally, producing immature myeloid cells, also called blasts, that transform into cancer,” according to the Seattle Cancer Care Alliance. Fortunately, companies are actively and aggressively trying to treat AML and other cancers, including WPD Pharmaceuticals Inc. (CSE:WBIO)(OTC:WPDPF), Moleculin Biotech, Inc. (NASDAQ:MBRX), NovoCure Ltd. (NASDAQ:NVCR), Guardant Health Inc. (NASDAQ:GH), and Mirati Therapeutics Inc. (NASDAQ:MRTX).
In fact, companies, like WPD Pharmaceuticals are finding that Annamycin, the company’s drug candidate used in the treatment of Acute Myeloid Leukemia is “considered one of the most effective groups of oncological drugs. Annamycin was originally developed for the treatment of relapsed or refractory acute AML. Unlike clinically used anthracyclines, Annamycin effectively penetrates cancer cells, regardless of the presence of MDR proteins, while maintaining high safety and lack of cardiotoxicity,” as noted in a company press release.